VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
1.580
-0.120 (-7.06%)
Mar 31, 2025, 4:00 PM EDT - Market closed
VYNE Therapeutics Employees
VYNE Therapeutics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.
Employees
13
Change (1Y)
3
Growth (1Y)
30.00%
Revenue / Employee
$38,538
Profits / Employee
-$3,064,154
Market Cap
23.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VYNE News
- 11 days ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 25 days ago - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics to Participate in March Investor Conferences - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire